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Abstract 
Background: It is unclear whether biomarkers of alveolar damage (surfactant protein D, SPD) or conductive airway 
damage (club cell secretory protein 16, CC16) measured early after intensive care admittance are associated with 
one‑month clinical respiratory prognosis. If patients who do not recover respiratory function within one month can 
be identified early, future experimental lung interventions can be aimed toward this high‑risk group. We aimed to 
determine, in a heterogenous critically ill population, whether baseline profound alveolar damage or conductive 
airway damage has clinical respiratory impact one month after intensive care admittance.
Methods: Biobank study of biomarkers of alveolar and conductive airway damage in intensive care patients was 
conducted. This was a sub‑study of 758 intubated patients from a 1200‑patient randomized trial. We split the cohort 
into a “learning cohort” and “validating cohort” based on geographical criteria: northern sites (learning) and southern 
sites (validating).
Results: Baseline SPD above the 85th percentile in the “learning cohort” predicted low chance of successful wean‑
ing from ventilator within 28 days (adjusted hazard ratio 0.6 [95% CI 0.4–0.9], p = 0.005); this was confirmed in the 
validating cohort. CC16 did not predict the endpoint. The absolute risk of not being successfully weaned within the 
first month was 48/106 (45.3%) vs. 175/652 (26.8%), p < 0.0001 (high SPD vs. low SPD). The chance of being “alive and 
without ventilator ≥20 days within the first month” was lower among patients with high SPD (adjusted OR 0.2 [95% 
CI 0.2–0.4], p < 0.0001), confirmed in the validating cohort, and the risk of ARDS was higher among patients with high 
SPD (adjusted OR 3.4 [95% CI 1.0–11.4], p = 0.04)—also confirmed in the validating cohort.
Conclusion: Early profound alveolar damage in intubated patients can be identified by SPD blood measurement 
at intensive care admission, and high SPD level is a strong independent predictor that the patient suffers from ARDS 
and will not recover independent respiratory function within one month. This knowledge can be used to improve 
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Background
Persistent ventilator-dependent respiratory failure is 
a major cause of death and prolonged admission to the 
intensive care unit [1]. Some patients suffer damage to 
the respiratory system during the intensive care course 
and do not recover the ability to breathe independently. 
Among other biomarkers of lung damage (e.g., surfactant 
protein A [2], soluble receptor for advanced glycation 
end products (sRAGE) [3] and Kerbs von Lungen [3]), 
surfactant protein D (SPD), produced by alveolar type II 
cells, has consistently shown to predict ARDS [2–5] and 
club cell secretory protein 16 (CC16, formerly known as 
Clara cell secretory protein-16) produced in the conduc-
tive airways has been claimed to have this ability also [3].
It is not known whether these biomarkers of alveo-
lar damage and conductive airway damage, respectively, 
can predict one-month clinical respiratory progno-
sis. Current measures of respiratory failure (e.g., PaO2/
FiO2 ratio) do not seem to capture which intensive care 
patients are at risk of persistent ventilator-dependent res-
piratory failure for one month or more.
Berlin ARDS criteria are highly useful in many patients 
for guiding treatment [6]; however, many patients with 
severe acute respiratory failure get excluded from the 
ARDS diagnosis because of lack of relevant radiological 
findings fulfilling the criteria, and some patients without 
alarming baseline PaO2/FiO2 ratios may have a very poor 
respiratory prognosis. Clinical focus in intubated patients 
has been largely centered on acute syndromes within the 
first week after admission. However, less attention has 
been given to one-month respiratory prognosis, a clini-
cally important endpoint.
SPD, a 43-kDa member of the collectin superfamily, is 
a part of lung surfactant and has been shown to have an 
important role in the innate immune system by working 
as a pattern recognition molecule [7]. Additionally, SPD 
promotes chemotaxis of antigen-presenting cells [8] and 
influences the function of lymphocytes and neutrophils 
[9, 10]. In a murine transgenic model, mice overexpress-
ing SPD seemed to be protected against lung damage in 
oxidative stress [11]. Increases in vascular phase SPD 
have been associated with acute lung injury and mortality 
[2].
Club cells are situated primarily in the terminal bron-
chioles [12]. The dominant secreted substance from these 
cells is CC16, a 16-kDa polypeptide involved in immu-
noregulation [13, 14]. CC16 decreases in chronic lung 
damage, and among smokers, CC16 is reduced propor-
tionally to the number of pack years [15]. CC16 increases 
in plasma when airways are stimulated with endotoxin 
[16]; however, this has been disputed [17]. These two bio-
markers represent ways of identifying alveolar damage 
(SPD) and conductive airway damage (CC16).
The primary aim of this study was, among patients with 
acute ventilator-dependent respiratory failure and com-
plete follow-up, to determine whether initial profound 
alveolar damage (high SPD) or damage to conductive 
airways (high CC16) is associated with ARDS and has a 
detectable clinical impact one month after intensive care 




This was a multicenter observational study based on the 
cohort of ICU patients recruited into the 1200-patient 
randomized controlled trial, the Procalcitonin And Sur-
vival Study (PASS) from 2006 to 2011 [18]. Data were col-
lected according to the Good Clinical Practice guidelines 
[19], and follow-up was complete on the measures in 
the case report forms. Regarding use of mechanical ven-
tilation, this was followed up for all patients, also when 
patients were discharged from the recruiting ICU and 
admitted to another ICU. All participants gave written 
informed consent, and ethical approval for the study was 
granted by the Regional Ethics Committee for Copenha-
gen and Frederiksberg Communes in Denmark (refer-
ences: KF 01 272 753, KF 11 297 287).
To be eligible for the PASS trial, patients had to be at 
least 18  years of age, enrolled within 24  h of admission 
to the intensive care unit, and have an expected inten-
sive care admission length of at least 24 h. Patients with 
known highly elevated bilirubin levels (≥40  mg/dL) or 
triglycerides (≥1000 mg/dL) were not eligible because of 
interference with procalcitonin measurements. Patients 
were recruited from nine ICUs across Denmark. In the 
PASS trial, patients were randomized to a proactive anti-
biotic strategy guided by biomarker levels (high-exposure 
group, n = 604) vs. a standard antibiotic strategy (stand-
ard exposure group, n  =  596). Two recent publications 
diagnostic and prognostic models and to identify the patients who most likely will benefit from experimental inter‑
ventions aiming to preserve alveolar tissue and therefore respiratory function.
Trial registration This is a sub‑study to the Procalcitonin And Survival Study (PASS), Clinicaltrials.gov ID: NCT00271752, 
first registered January 1, 2006
Keywords: Lung damage, Mechanical ventilation, Biomarkers, Personalized early intervention
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from the study describe the details [20, 21]. Mortality was 
unchanged by the antibiotic intervention [18]. The popu-
lation for the current study was all primarily intubated 
patients from the PASS trial with sufficient serum for the 
bio-analysis at baseline (n  =  758). The population was 
split into two subpopulations according to the geographi-
cal position of the site where the patient was recruited: 
a northern “learning cohort” (n  =  405) and a southern 
“validating cohort” (n = 353). The study material includes 
a biobank with serum from all patients from all days in 
the ICU (n =  9915 samples). For simplicity, one month 
was defined as 28 days.
Biomarker measurement
Serum levels of SPD and CC16 were measured at base-
line in uniplicate by commercially available ELISA assays 
(BioVendor Research Products ELISA kit, Brno, Czech 
Republic). The lower limits of detection were 0.01 ng/ml 
in the SPD kit and 0.046 ng/ml in the CC16 kit, respec-
tively. No measurements were below the detection rate. 
Samples above the calibration interval were diluted.
Outcome assessment
Several endpoints were assessed in the analyses to 
explore the hypothesis:
1. “Not successfully weaning from mechanical ventila-
tion within 28 days”: A patient who was weaned from 
respirator within 28 days and not re-intubated within 
the same period was considered to have been suc-
cessfully weaned. Death within 28  days was consid-
ered a competing in these analyses.
2. “Alive and without ventilator ≥20  days within the 
first month”: Since death was frequent in this cohort 
(as in other ICU cohorts), we explored a combined 
“favorable” outcome of surviving and being inde-
pendent of mechanical ventilation for ≥20 days.
3. ARDS according to the Berlin Criteria [6]: The end-
points were assessed using the case report form while 
in the initial ICU and post-ICU by finding all admis-
sions to departments in Denmark; if the department 
was not able to administer mechanical ventilation, it 
was assumed that the patient was not using mechani-
cal ventilation. If the department could administer 
mechanical ventilation, the patient chart was located 
and read to ascertain whether the patient received 
mechanical ventilation. Radiology was registered in 
the case report form. Bilateral opaque infiltrates not 
fully explained by other causes were considered sus-
picious for ARDS and were combined with the PaO2/
FiO2 ratio in the definition. An ICU specialist judged 
whether the patient had ARDS (acute diagnosis in 
the case report form).
Statistical analyses
Comparisons of continuous data were made using Stu-
dent’s t tests and Mann–Whitney U tests where appro-
priate. Chi-square tests for equal proportions were used 
to test categorical variables; at small numbers, Fisher’s 
exact test was used. Time-to-event analyses were per-
formed using Cox proportional hazards models and 
Kaplan–Meier plots with corresponding log-rank tests. 
For analyses of persistent respiratory failure, a compet-
ing risk model was applied to account for the effect of 
deaths during follow-up. Multivariable analysis of the 
primary endpoint was performed adjusting for known 
and suspected predictors of persistent respiratory fail-
ure: surfactant protein D ≥85th percentile (≥525.6  ng/
mL), club cell secretory protein 16  ≥  85th percentile 
(≥42.75  ng/mL), lowest quartile PaO2/FiO2 ratio (vs. 
quartile 2-4), APACHE II score (continuous), age (con-
tinuous), severe sepsis/septic shock (present vs. not), 
chronic obstructive lung disease (COPD, yes vs. no), 
Charlson’s score ≥2 (vs. <2), gender (male vs. female) 
and estimated glomerular filtration rate (continuous). 
“Alive and without ventilator ≥20  days within the first 
month” and “ARDS” were analyzed using multivariable 
logistic regression analysis.
A power calculation was done for the smallest cohort. 
Conditions for the calculation were as follows: sam-
ple size 353, conventional border for type I error (0.05), 
exposure variable present in 15% (biomarker level above 
85% percentile), endpoint (successful weaning within 
28  days) present in 55% patients in the high-level bio-
marker group, variance inflation factor of 0.2 and detec-
tion limit of hazard ratio in a Cox proportional hazards 
model of 0.60. This resulted in a power of 0.80. Power 
calculation was done using the Study Size 3.0 package, 
Creostat, Frölunda, Sweden. Statistical analyses were 
performed using SAS version 9.3 (SAS Institute Inc, 
Cary, NC) and “R” version 3.0.2 (The R-project, http://
www.r-project.org/).
The study was initiated and run by doctors at our 
research department (CHIP, Rigshospitalet) and the par-
ticipating intensive care units (ICU). All data belong to 
the PASS study group.
Results
Between January 2006 and June 2011, nine intensive care 
units in Denmark recruited and followed 1200 critically 
ill patients. Serum was collected for all patients on all 
ICU days; however, in 75 patients, not enough serum was 
available to perform ELISA analysis. Additionally 367 
patients were not intubated at baseline; 758 patients were 
included in the current study (Fig. 1), 405 in the “learning 
cohort” and 353 in the “validating cohort.” The baseline 
characteristics in the two cohorts are given in Table 1; the 
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most common primary reason for admission to the ICU 
was infection of different types, as given in Table 1.
Follow-up within 28  days after inclusion was complete 
both for the primary endpoint (weaning from ventilator-
demanding respiratory) and for mortality in both cohorts.
The highest levels of SPD were found in patients with 
pneumonia and heart failure as primary cause of ICU 
admission (Fig.  2); no differences were noted for CC16 
between any diagnostic categories (not shown).
Successful weaning from mechanical ventilation 
within 28 days
Failure to be successfully weaned from mechanical ven-
tilation within 28 days was observed 105/405 (25.9%) in 
the “learning cohort” and 118/353 (33.4%) in the “validat-
ing cohort.” Death from all causes was considered a com-
peting risk in all Cox regression analyses.
Patients with SPD above the 85th percentile 
(≥525.6 ng/mL) in the “learning cohort” were less likely 
to be successfully weaned from ventilator (adjusted HR 
0.6 [95% CI 0.4–0.9], p  =  0.0053); no association was 
found for CC16, and apart from SPD, only APACHE II 
score and severe sepsis/septic shock independently pre-
dicted reduced probability of successful weaning from 
mechanical ventilation within 28 days, Cox regression, as 
given in Table 2. After proposing and analyzing the 85th 
percentile cutoff in the “learning cohort”/northern cohort 
at 525.6 ng/mL SPD, all the above analyses were repeated 
in the “validating cohort”/southern cohort, using the 
cutoff established in the “learning cohort” (525.6 ng/mL). 
The signal was unchanged; high SPD independently pre-
dicted a reduced chance for the patient successfully to 
be weaned from mechanical ventilation within 28  days 
(adjusted HR 0.6 [95% CI 0.4–1.0], p = 0.046, Table 2).
Since the population was heterogenous, the above 
analyses were repeated in both cohorts after excluding 
patients considered to have a some degree of non-revers-
ible cause of persistent respiratory failure (heart failure, 
severe neurological disease and chronic interstitial lung 
disease); the signal was unchanged: northern (learning) 
cohort (n = 346): SPD ≥ 525.6 ng/mL: adjusted HR 0.6 
[95% CI 0.4–1.0, p  =  0.028] and southern (validating) 
cohort (n = 300): SPD ≥ 525.6 ng/mL: adjusted HR 0.6 
[95% CI 0.4–1.0, p = 0.050].
The hazard function for successful weaning from 
mechanical ventilation according to SPD serum level 
(the 15% patients with highest SPD, ≥525.6  ng/mL) for 
the entire cohort (n =  758) seemed not only to be dif-
ferent in the early course of the ICU admission; curves 
separate increasingly throughout the 28-day observation 
period, and patients with high SPD also had a substan-
tially increased incidence of death while intubated, as 
shown in Fig. 3.
Alive and without ventilator ≥20 days within the first 
month
In the learning cohort, 211 of 405 patients were “alive 
and without ventilator ≥20 days within the first month.” 
Fig. 1 Flowchart of patients in the study. PASS: the Procalcitonin And Survival Study, a 1200‑patient intensive care randomized trial [21]
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In the validating cohort, this number was 154/353. In 
both cohorts, SPD ≥85th percentile (≥525.6  ng/mL) 
was an independent predictor of the patient being “alive 
and without ventilator ≥20 days within the first month” 
(Fig. 4).
“Acute respiratory distress syndrome” according to Berlin 
criteria
In total, 31 (4.1%) patients fulfilled the ARDS Berlin defi-
nition at admission to the ICU. All patients were assessed 
for ARDS at baseline, but were not followed for this after 
discharge from the ICU. High SPD also independently 
predicted ARDS at baseline; however, CC16 did not pre-
dict these endpoints (Table 3).
Patients with SPD ≥85th percentile (≥525.6  ng/mL) 
also had a high incidence of death from all causes as 
compared with patients with an SPD <85th percentile, as 
shown in Additional file 1: eFig 1.
Discussion
The current study shows, in a well-defined cohort of 
758 intubated critically ill patients, that profound alveo-
lar damage at ICU admission, measured using SPD, 
increases the risk that the patient has ARDS, and sub-
stantially reduces the chance that patients can breathe 
on own conditions, without mechanical ventilation, one 
month after admission to the intensive care unit. Patients 
with high SPD also had a high risk of 28-day all-cause 
mortality. To acknowledge the competing risk of death, 
the main analysis was performed as a competing risk 
model. Additionally, an analysis of the endpoint “alive 
and without ventilator ≥20 days within the first month” 
was performed. The signal was unchanged; a high SPD 
was an independent predictor of this endpoint also. The 
effect was detected in a “learning cohort” and validated 
in a “validating cohort,” geographically separated. Results 
in both cohorts were robust to adjustment for nine other 
Table 1 Baseline characteristics of the patients in the two cohorts
y, years; IQR, interquartile range; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate—calculated by the Cockroft–Gault formula
Learning cohort (northern)  
N = 405
Validating cohort (southern) 
N = 353
Age (year) (median, IQR) 68 (59–77) 67 (57–75)
Apache II score (median, IQR) 21 (15–28) 19 (14–25)
Body mass index (kg/m2, median, IQR) 24.7 (22.8–27.7) 24.7 (22.2–27.7)
eGFR (ml/min/1.73 m2) 48.5 (26.4–78.9) 58.8 (33.5–93.5)
PaO2/FiO2 (Kpa, median, IQR) 19.4 (11.6–29.2) 21 (13.6–28.9)
Surfactant protein D (ng/mL, median, IQR) 133.5 (77.3–308.0) 112 (63.5–240.7)
Club cell secretory protein 16 (ng/mL, median, IQR) 25.4 (10.6–37.4) 20.2 (7.7–37.9)
Severe sepsis/septic shock, n (%) 158 (39.0) 149 (42.2)
Charlson’s comorbidity index, n (%)
 0 130 (32.1) 136 (38.5)
 1 139 (34.3) 108 (30.6)
 2 79 (19.5) 65 (18.4)
 3 34 (8.4) 30 (8.5)
 4 13 (3.2) 8 (2.3)
 5 6 (1.5) 2 (0.6)
 6 4 (1.0) 3 (0.9)
 7 0 (0.0) 1 (0.3)
COPD, n (%) 81 (20.0) 75 (21.3)
Primary admittance cause/acute diagnosis category (%)
 Pneumonia 137 (33.8) 117 (33.1)
 Abdominal sepsis 65 (16.1) 76 (21.5)
 Sepsis of other cause 48 (11.9) 42 (11.9)
 Heart failure 47 (11.6) 34 (9.6)
 Thrombosis or bleeding 52 (12.8) 20 (5.7)
 Other 56 (13.8) 64 (18.1)
Gender, n (%)
 Female 184 (45.4) 163 (46.2)
 Male 221 (54.6) 190 (53.8)
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known or suspected predictors of respiratory failure [22, 
23]. Additionally, the association is biologically plausible, 
since SPD is a documented part of the alveolar surfactant 
with immunological properties as a pattern recognition 
molecule, and serum SPD increases when alveolar dam-
age emerges so a leakage to the blood can occur [7, 24, 
25]. Almost half of the patients with high SPD were not 
capable of breathing on own conditions after one month 
Fig. 2 Surfactant protein D serum levels according to primary admission reason. a “Learning cohort”/northern sites. b “Validating cohort.” Boxes are 
medians and interquartile ranges. Whiskers are total range. Rhombuses are means
Table 2 Predictors of successful weaning from mechanical ventilation within 28 days—multivariable competing risk Cox 
regression
Adjusted Cox regression risk estimates for known, suspected and explored predictors of successful weaning from ventilator within 28 days. Death from all causes was 
entered in the model as a competing risk
Q1, quartile 1; eGFR, ml/min/1.73 m2
Learning cohort (northern) N = 405 Validating cohort (southern) N = 353
P value Hazard ratio 95% CI for HR P value Hazard ratio 95% CI for HR
Lower Upper Lower Upper
Surfactant protein D (≥85th percentile in “learning cohort,” 
≥525.6 ng/mL vs. <525.6 ng/mL)
0.0053 0.60 0.42 0.86 0.046 0.64 0.42 0.99
Club cell secretory protein 16 (≥85th percentile in “learning 
cohort,” ≥42.8 ng/mL vs. <42.8 ng/mL)
0.50 0.89 0.66 1.22 0.81 0.96 0.67 1.37
PaO2/FiO2 (Q1 vs. Q2–Q4) 0.017 0.73 0.57 0.95 0.89 0.98 0.73 1.32
Apache II score (per score unit increase) 0.031 0.986 0.974 0.999 0.041 0.981 0.964 0.999
Age (per year increase) 0.84 1.00 0.992 1.010 0.17 0.993 0.984 1.003
Severe sepsis/Septic shock (vs. milder or no infection) 0.0014 0.66 0.51 0.85 0.0019 0.63 0.48 0.85
Charlson’s comorbidity index ≥2 vs. <2 0.046 1.29 1.00 1.67 0.58 1.08 0.81 1.46
Chronic obstructive pulmonary disease (yes vs. no) 0.36 0.87 0.64 1.18 0.71 0.94 0.67 1.31
Gender (male vs. female) 0.82 0.97 0.77 1.23 0.97 1.01 0.77 1.32
Estimated glomerular filtration rate (per ml) 0.61 1.00 0.999 1.002 0.048 1.001 0.998 1.004
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was reached, compared to approximately one-fourth of 
those with SPD below the cutoff.
Opposite, CC16, a marker primarily produced in the 
conductive airways, did not predict the endpoint in any 
analysis.
The current results should be interpreted in context 
to the not easily recognized pathophysiological changes 
taking place in acute ventilator-dependent respiratory 
failure, sometimes leading to the clinical picture of acute 
respiratory distress syndrome (ARDS): diffuse damage 
to alveolar epithelial cells, including alveolar type II cells 
and vascular endothelium, breakdown of the basal mem-
brane in the alveoli and consequent leakage of surfactant 
components to the blood. This is accompanied by hem-
orrhagic intra-alveolar deposition of platelets, protein 
and fibrin components eventually forming hyaline mem-
branes [26].
Thus, our results indicate that patients who have an 
early increase in SPD more often progress into patho-
physiological changes that are not easily reversible and 
changes that cause the phenotype of persistent ventila-
tor-dependent respiratory failure. Our findings regarding 
PaO2/FiO2 ratio, an important acute parameter for the 
ICU physician, underline the need for pathophysiologi-
cal markers like SPD to identify patients at early risk of 
persistent respiratory failure, since an unfavorable PaO2/
FiO2 ratio in the lowest quartile was not a consistent pre-
dictor of poor respiratory prognosis after one month.
The knowledge provided by measuring SPD early does 
have important implications for predicting outcome, and 
it does increase the understanding of how and when the 
decisive pathophysiological steps leading to this feared 
clinical syndrome occur, but even more importantly, 
this knowledge could help at admission, identifying the 
most suitable candidates for trials applying experimen-
tal lung interventions in patients at high risk of develop-
ing persistent respiratory failure. Prone positioning has 
been demonstrated to be effective in patients with ARDS 
[27]; however, our results suggest that patients with a 
predicted high risk of persistent respiratory failure (i.e., 
highest SPD) should be enrolled in trials testing experi-
mental lung interventions even before ARDS develops, in 
order to improve the prognosis [28]. ARDS awareness is 
of key importance in these vulnerable patients, so timely 
and effective interventions can be initiated. However, 
current reports show that ARDS is often not recognized, 
even when present [22]. Additionally, many patients 
who end up with persistent respiratory failure after one 
month may not have fulfilled ARDS criteria previous to 
this, and in some patients, an early warning by a bio-
marker, before ARDS develops, may provide a possibility 
for early intervention, even before clinical signs of poor 
prognosis can be realized. Thus, it seems reasonable to 
supplement increasing ARDS awareness with biomarkers 
of acute lung damage like SPD and probably others. In a 
rat model of ARDS, soluble receptor for advanced gly-
cation end products (sRAGE) seemed to reflect alveolar 
type I cell injury, and this was also observed in humans 
[29, 30], and recently, it has been demonstrated that a 
strong negative correlation exists between alveolar fluid 
clearance rate and plasma sRAGE in a murine model as 
well as in humans [31]. Thus, sRAGE and SPD may pro-
vide complementary information on the pathophysiologi-
cal changes taking place in the alveolar epithelium.
This knowledge does draw the attention to two issues 
of pivotal importance: i) that novel and experimental 
alveoli-protecting interventions should be instituted in 
a personalized manner—what works for one critically ill 
patient (with altered SPD, sRAGE and possibly other sig-
nals of profound lung damage) may not work for another 
patient with low SPD and no other significant signs of 
profound lung damage, and ii) that in patients with early 
signs of profound lung damage, experimental alveoli-pro-
tecting interventions should probably be tested in trials 
to reduce development of long-term respiratory failure.
Fig. 3 Cumulative incidence of successful weaning from respira‑
tor within 28 days after intensive care admission and death while 
intubated—total cohort (“learning”/northern cohort + “validating”/
southern cohort). The two upper curves are regarding “successful 
weaning from respirator” (vs. still intubated at day 28); the two lower 
curves are regarding “dead while intubated” (vs. alive at day 28). 
Patients extubated <48 h at death were counted as “dead while intu‑
bated.” Patients extubated and alive at day 28 and those extubated 
≥48 h at death were counted as successfully weaned from ventilator. 
N = 758. Gray scales are 95% CI. SPD surfactant protein D. “High SPD is 
>525.6 ng/mL
Page 8 of 11Jensen et al. Ann. Intensive Care  (2016) 6:114 
Strengths and limitations
The current study is an observational study with the 
built-in limitations this implies. Not all patients in the 
cohort had lung biomarker measurements (75 patients 
in the cohort had insufficient volume of serum, and we 
cannot expand our conclusions to the patients where 
biomarker measurements were not taken). We cannot 
document that awareness of ARDS was sufficient; how-
ever, this is not unique to our cohort [22]. Many factors 
that occur after the initial event that led to ICU admis-
sion may have influenced the development of persistent 
respiratory failure, which are tidal volumes, PEEP adjust-
ments and the timing of these, transfusions, critical ill-
ness neuropathy and others. We could not control for all 
these factors, and especially timing of PEEP adjustments 
are, to some extent, still disputed. However, factors not 
present at baseline and therefore not possibly captured 
by the biomarkers at baseline will tend to underestimate 
the predictive power of the biomarkers. Optimally, bio-
markers of lung damage should have been measured 
daily. The strengths of the study are (1) the relatively high 
sample size, (2) the complete follow-up for the endpoints 
Fig. 4 Adjusted odds ratios for the patient being “alive and without mechanical ventilation for ≥20 days within first 28 days after ICU admission.” All 
variables were entered in the same logistic regression model. The graph is separated to display odds ratios for both binary and continuous covari‑
ates. Cut points for SP‑D and CC16 are equal to upper 15 percentile in the northern/learning cohort. Boxes and whiskers are odds ratio and 95% CIs, 
respectively
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due to good clinical practice-based clinical monitoring 
and follow-up based on the Danish hospital registers and 
(3) the completeness of data on a wide variety of clini-
cal, biochemical, radiological and microbiological data in 
these patients.
Optimally, the results should be validated in another 
cohort of intubated ICU patients with complete follow-
up on mechanical ventilation and mortality for 28 days, 
and where these two biomarkers were analyzed. Since 
we could not identify such a population by searching 
PubMed and EMBASE, we decided to split the cohort 
up according to geographical criteria to mimic that the 
validating cohort was another cohort. This strategy can 
be criticized, and our results should be further validated.
In summary, a high SPD level at baseline is associated 
with a very high absolute risk of the patient not being 
successfully weaned from mechanical ventilation within 
a month, and a high risk of dying while intubated. When 
adjusted for other predictors of respiratory failure, high 
SPD level at baseline independently predicts persistent 
respiratory failure during mechanical ventilation in criti-
cally ill patients. Acknowledging that ICU populations 
are often heterogenous and that other reasons may have 
accounted for some of the cases of persistent respiratory 
failure, we repeated all the main analyses while excluding 
patients with heart failure, chronic interstitial lung disease 
and severe neurological diseases; all these analyses con-
firmed the findings regarding the lung damage biomarkers.
The results from the current study indicate that high 
impact insults on the lungs, early in the ICU course, 
contribute substantially to the development of later per-
sistent respiratory. Importantly, early SPD blood measure-
ments can reveal evidence of such profound lung damage. 
This knowledge could be used in updated diagnostic 
and prognostic models regarding respiratory failure and 
ARDS in critically ill patients. If our results regarding SPD 
and prognosis can be verified in other cohorts, SPD meas-
urements could be added to the ARDS criteria, since SPD 
seems to predict both respiratory prognosis and overall 
prognosis and, importantly, is linked to pathophysiology 
taking place in the alveoli. Additionally, SPD measure-
ments could be used to select patients for trials on novel 
experimental lung interventions initiated in high-risk 
patients at ICU admission before ARDS and eventually 
irreversible/persistent respiratory failure develops.
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Additional file 1. Death from all causes according to level of surfactant 
protein D. Y‑axis is cummulative risk of death. Bold line is for patients with 
low surfactant protein D; stipulated line is for patients with high surfactant 
protein D. Grey areas are 95% confidence intervals.
Table 3 Acute respiratory distress syndromea according to Berlin criteria—multivariable logistic regression
Adjusted logistic regression risk estimates for known, suspected and explored predictors of ARDS. Abbreviations: Q1: quartile 1
Biomarker levels were not known for radiologists and ICU physicians who diagnosed ARDS
OR, odds ratio
a All severities (mild, moderate, severe) of ARDS were counted
Learning cohort (northern)  
N = 405
Validating cohort (southern) 
N = 353
P value Odds 
ratio
95% CI for OR P value Odds 
ratio
95% CI for OR
Lower Upper Lower Upper
Surfactant protein D (≥85th percentile in “learning cohort,” 
≥525.6 ng/mL vs. <525.6 ng/mL)
0.042a 3.4 1.0 11.4 0.003a 8.4 2.0 35.4
Club cell secretory protein 16 (≥85th percentile in “learning cohort,” 
≥42.8 ng/mL vs. <42.8 ng/mL)
0.14 2.6 0.7 9.7 1.0 0.96 0.20 4.5
PaO2/FiO2 (Q1 vs. Q2‑Q4) 0.076 2.9 0.9 9.1 0.001
a 9.3 2.6 33.7
Apache II score (per score unit increase) 0.23 1.025 0.984 1.067 0.57 1.023 0.946 1.106
Age (per year increase) 0.56 1.015 0.965 1.067 0.26 0.974 0.93 1.02
Severe sepsis/septic shock (vs. milder or no infection) 0.19 2.1 0.68 6.8 0.06 3.6 0.96 13.6
Charlson’s comorbidity index ≥2 vs. <2 0.23 0.41 0.10 1.7 0.12 0.28 0.053 1.42
Chronic obstructive pulmonary disease (yes vs. no) 0.74 0.76 0.15 3.8 0.65 1.43 0.30 6.7
Gender (male vs. female) 0.32 0.56 0.18 1.74 0.67 1.30 0.40 4.2
Estimated glomerular filtration rate (per ml increase) 0.19 1.005 0.998 1.011 0.61 1.003 0.992 1.01
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